Background: Hibiscus sabdariffa L. is a tropical wild plant rich in organic acids, polyphenols, anthocyanins, polysaccharides, and volatile constituents that are beneficial for the cardiovascular system. Hibiscus sabdariffa beverages are commonly consumed to treat arterial hypertension, yet the evidence from randomized controlled trials (RCTs) has not been fully conclusive. Therefore, we aimed to assess the potential antihypertensive effects of H. sabdariffa through systematic review of literature and meta-analysis of available RCTs.
INTRODUCTION
C onsidering the high prevalence of hypertension, its control, therapy, complications, and the side effects of drugs used for its treatment [1, 2] , the natural compounds rich in phytochemicals should be always considered as an attractive alternative for control and prevention of this disease [3] .
There are more than 300 species of Hibiscus around the world. One of them is Hibiscus sabdariffa Linn. -a member3-glucoside), sabdaritrin, gossypitrin, gossytrin, and other gossypetin glucosides, quercetin and luteolin [13] . Since H. sabdariffa is an aromatic plant, it also contains volatile constituents as described elsewhere [14] .
Among the medicinal properties of H. sabdariffa, reduction of blood pressure (BP) has been the most widely investigated [15] [16] [17] . Different studies have compared the efficacy of H. sabdariffa to some antihypertensive drugs. As for example, the standardized extract of H. sabdariffa (containing 9.6 mg total anthocyanins) was compared with captopril 50 mg/day, and the results revealed comparable hypotensive effect, and tolerability in hypertensive patients [15] . In another study, dried extract of H. sabdariffa calyxes containing 250 mg total anthocyanins was compared to 10 mg of lisinopril [16] . The exerted antihypertensive effects with a wide margin of tolerability and safety in patients with stage I or II of hypertension were observed, though the efficacy was lower than for lisinopril [16] . Hibiscus sabdariffa has also diuretic capacity owing to its antioxidant properties and high potassium content, causing BP reduction that is comparable with that of furosemide [18] .
Many experimental and clinical studies have evaluated H. sabdariffa efficiency as a medication for arterial hypertension therapy based on the ethnomedicinal, pharmacological, and phytochemical properties [9, 15, 18, 19] . However, the results of these studies were based on relatively small sample sizes, and are not fully conclusive. Therefore, the precise effect of H. sabdariffa supplementation has not been still established. The purpose of this meta-analysis was to investigate the impact of H. sabdariffa supplementation on SBP and DBP. As far as we are aware, this is the first systematic review and meta-analysis on this topic.
METHODS

Data sources
The present study was designed in conformity to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [20] . Our literature search included MEDLINE, Cochrane Library, Scopus, and EMBASE databases, and was limited to randomized controlled trials (RCTs) investigating the efficacy of sour tea (H. sabdariffa) supplementation on arterial hypertension that were published up to 1 July 2014. The references in all retrieved articles were searched for additional relevant publications. Each search strategy included keywords related to H. sabdariffa and search terms of interest, including systolic or diastolic arterial hypertension. Two reviewers (C.S. and S.U.) assessed each article independently to diminish the probability of duplication, analyzing reviews, case studies, and uncontrolled trials. Disagreements were resolved by consensus and discussion with a third party (M.B.). Studies were excluded if they were uncontrolled or their results did not consider the main goals of the analysis.
Study selection
Inclusion criteria Study design had to meet the following criteria: randomized, placebo-controlled parallel or cross-over trial; population enrolled: adults at least 18 years; SBP and DBP data at baseline and after consumption of H. sabdariffa preparations were available.
Exclusion criteria
Studies were excluded under the following conditions: compared sour tea with different drugs; no numerical values were provided regarding SBP and/or DBP at baseline or study end; the study did not include a control group; and ongoing trials.
Quality assessment
The quality of involved studies in this meta-analysis was evaluated using Jadad scale [21] . This scale includes randomization (0-2 points), blinding (0-2 points), and dropouts and withdrawals (0-1 point). The overall score of a study in accordance with this scale varies among 0-5, with greater scores as a measure of better quality [21] .
Quantitative data synthesis
Meta-analysis was conducted using the Cochrane Program Review Manager Version 5.1 (Cochrane Collaboration, Oxford, UK). Since all studies used the same methods for the BP measurement, weighed unstandardized mean difference 95% confidence interval (CI) was used as a summary statistic. Mean difference in measurements was calculated as follows: (measure at end of follow-up in the treatment group -measure at baseline in the treatment group) -(measure at end of follow-up in the control groupmeasure at baseline in the control group). SDs of the mean difference were calculated using the following formula:
2 -(2R Â SDpre-treatment Â SDpost-treatment), assuming a correlation coefficient (R) ¼ 0.5 [22, 23] . A fixedeffect model and the generic inverse variance method were used for quantitative data synthesis. Pooled effect size was expressed as unstandardized weighed mean difference (WMD) with 95% CI. In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the one-study remove (leave-oneout) approach [22, 24] . The proportion of inconsistency across the included studies, which is not attributable to chance (heterogeneity), was quantified using Cochran Q test and I 2 indices [22, 25] . In order to avoid double-counting of patients and consequent unit-of-analysis error in the trials with more than one treatment arm, the control group was evenly (when possible) divided into two sections. In case the values were only presented as graph, the software GetData Graph Digitizer 2.24 (http://getdata-graph-digitizer. com/) was applied to digitize and extract the data.
Meta-regression
Fixed-effect meta-regression was performed to assess the potential impact of baseline SBP and DBP values on the WMD calculated for each respective parameter [22, 26] . Meta-regression analysis was performed using comprehensive meta-analysis (CMA) V2 software (Biostat, New Jersey, USA) [27] .
Assessment of publication bias
Presence of publication bias was explored graphically using funnel plots of precision (1/standard error) by study effect size (mean difference). Asymmetric funnel plots were further assessed for publication bias using Duval and Tweedie 'trim-and-fill' and 'fail-safe N' methods, as well as Begg's rank correlation and Egger's weighted regression tests [22, 27] . All publication bias analyses were performed using CMA V 2 software (Biostat) [26] .
RESULTS
A summary of the study selection process is shown in Fig. 1 . The initial screening for potential relevance excluded articles whose titles and/or abstracts were clearly irrelevant. After removing the trials not assessing the effects of H. sabdariffa extracts on arterial hypertension, only seven RCTs met the inclusion criteria and the full texts were obtained. Two trials that compared H. sabdariffa with captopril and lisinopril were excluded from the final meta-analysis [15, 16] . After assessment, five articles met the inclusion criteria and were selected for the final meta-analysis [3, 4, 9, 28, 29] .
Description of studies
In total, 390 participants were randomized, of whom 225 were allocated to the H. sabdariffa supplementation group and 165 to the control group in the five selected studies [3, 4, 9, 28, 29] . The number of participants in these trials ranged from 53 to 124. Included studies were published between 1999 and 2013, and were conducted in the United States, Mexico and Iran (three studies). A range of doses from 3.75 g/day to two spoonfuls or 100 mg of aqueous H. sabdariffa extract were administered in the included trials. Duration of supplementation with sour tea ranged between 15 days and 6 weeks. All trials were designed as parallelgroup studies. One trial [4] had three arms comparing H. sabdariffa extract powder vs. diet in healthy individuals, H. sabdariffa extract powder vs. diet in patients with metabolic syndrome, and H. sabdariffa extract powder þ diet vs. diet in patients with metabolic syndrome. Demographic and baseline parameters of the included studies are shown in Table 1 . Hibiscus sabdariffa was safe and well tolerated in all the RCTs included in this review, with no report of serious adverse events.
Quantitative data synthesis
As mentioned above, five studies met the inclusion criteria to be included in the meta-analysis. One of the trials [4] had three treatment arms; therefore, the final analyses were performed with seven treatment arms. Pooled estimates of effect size for the impact of sour tea on SBP (WMD À7.58 mmHg, 95% CI À9.69 to À5.46, P < 0.00001) and DBP (WMD À3.53 mmHg, 95% CI À5.16 to À1.89, P < 0.0001) were both significant. Forest plots detailing the meta-analysis of trials on SBP and DBP are presented on Figs. 2 and 3.
The strength of the estimated effect sizes for the impact of sour tea on SBP and DBP was robust in sensitivity analyses and did not significantly differ according to the characteristics of the original studies. The results of sensitivity analysis are shown in Tables 2 and 3 .
Meta-regression
Meta-regression analysis was performed to evaluate the potential impact of SBP and DBP on the calculated net effects of sour tea supplementation on each respective parameter. Fixed-effect meta-regression indicated a significant inverse association between baseline SBP and SBPlowering (slope À0.27, 95% CI À0.43 to À0.20, P ¼ 0.0005), and baseline DBP and DBP-lowering (slope À0.27, 95% CI À0.44 to À0.10, P ¼ 0.002) effects of H. sabdariffa supplementation. Meta-regression plots are presented in Figs. 4 and 5.
Risk of bias in included studies
Visual inspection of funnel plot asymmetry suggested potential publication bias for the effects of sour tea on 
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Journal of Hypertension www.jhypertension.comSBP (Fig. 6 ). The 'trim-and-fill' method imputed two theoretically missing studies, leading to an imputed effect size (WMD À9.48 mmHg, 95% CI À11.54 to À7.43) that was larger but not statistically significant from the initial estimate. The 'fail-safe N' test showed that 50 theoretically missing studies would be needed to add to the analysis of the effect of sour tea on SBP in order to yield a statistically nonsignificant overall effect. Consistently, Begg's rank correlation test (Kendall's Tau with continuity correction ¼ 0.48, Z value ¼ 1.50, two-tailed P value ¼ 0.13) and Egger's linear regression test (intercept ¼ 6.39, 95% CI À3.43 to 16.20, t value ¼ 1.67, DF ¼ 5.00, two-tailed P ¼ 0.16) suggested no evidence of publication bias. The funnel plot for the impact of sour tea on DBP was not asymmetric (Fig. 7) . The 'trim-and-fill' method did not impute any study, and the 'fail-safe N' test suggested a need to add 20 theoretically missing studies in order to yield a statistically nonsignificant overall effect. Likewise, there was no evidence of publication bias 
DISCUSSION
In this systematic review and meta-analysis, we summarized published evidence from five RCTs (comprising seven treatment arms) that investigated the effects of supplementation with H. sabdariffa in SBP and DBP-lowering. The results indicated a significant antihypertensive effect of sour tea supplementation on both SBP and DBP. The exact mechanisms responsible for these effects of H. sabdariffa are not completely understood. An experimental study [31] investigated the effect of the water extract of the dried calyx of H. sabdariffa and anthocyanins on the left ventricular myocardial capillary length and surface area in spontaneously hypertensive rats. The extract significantly reduced SBP and left ventricular mass in a dose-dependent fashion, and increased surface area and length density of the myocardial capillaries [31] . The inhibition of calcium (Ca 2þ )-influx into vascular smooth muscle cells and the vasodilator effect mediated through the endotheliumderived nitric oxide-cyclic guanosine monophosphate (cGMP)-relaxant pathway could be responsible for the antihypertensive effect of H. sabdariffa in the isolated aortic rings of hypertensive rats [32] . Polyphenols from H. sabdariffa crude extracts induced an endotheliumdependent relaxant effect via stimulation of nitric oxide synthase (NOS) enzyme by phosphatidylinositol-3-kinase/ protein kinase B pathway in the isolated thoracic aorta of rats [32] . The nonendothelium-dependent relaxation was a direct smooth muscle activation resulting from activation of smooth muscle potassium channels [33] . Furthermore, aqueous H. sabdariffa extract containing delphinidin-3-O-sambubioside and cyanidin-3-O-sambubioside anthocyanins inhibited the angiotensin-converting enzyme (ACE) activity, causing an additional antihypertensive effect [34] . Histopathological examinations also showed that H. sabdariffa extract reduces foam cell formation and inhibits smooth muscle cell migration and calcification in the blood vessel of rabbits [12] . The hypotensive activity of H. sabdariffa may be also outlined by a decrease of blood viscosity via the inhibitory activity of cyclooxygenase [35] , and inhibition of the differentiation of adipocytes via the modulation of phosphoinositide-3-kinase-protein kinase B/Akt (PI3-K/Akt) and extracellular-signal-regulated kinase (ERK) pathway [11] .
Analyzing all flavonoids that may be founded in H. sabdariffa extracts, quercetin has been shown to be the most powerful antihypertensive agent in different experimental and clinical studies [36, 37] . The potential responsible mechanisms underlying the antihypertensive effect of quercetin are vasodilation, reactive oxygen species Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension scavenger effect, inhibition of nicotinamide adenine dinucleotide phosphate-oxidase, modulator of the endothelial function, vascular smooth muscle cells [37] . It has been shown that quercetin generates a gradual, continued, and dose-dependent decrease in BP when it is offered chronically in generally all experimental models of hypertension, separately of the status of the nitric oxide, oxidative stress, or renin-angiotensin system [38, 39] . It was showed that an increased dose of quercetin decreased BP in stage 1 hypertensive patients [40] . Another component of H. sabdariffathe protocatechuic acid -inhibits the oxidation of lowdensity lipoprotein induced by either copper or a nitric acid donor [41] . Furthermore, cyanidin-3-sambubioside and delphinidin-3-sambubioside -known as competitor inhibitors of ACE activity -could be also responsible for the BPlowering effect of H. sabdariffa [33, 42] .
In another meta-analysis, the authors included 4 RCTs and 390 patients, and evaluated the efficiency and safety of H. sabdariffa in primary hypertensive patients [43] . Hibiscus sabdariffa decreased BP higher than black tea, but not as much as ACE inhibitors. However, the short-term and not enough quality of evaluated RCTs did not offer enough proofs to indicate H. sabdariffa for the treatment of primary BP [43] .
Several experimental and clinical studies have shown that oxidative stress plays an important role in arterial hypertension by adversely affecting vascular endothelial and smooth muscle cell functions [44, 45] . The ability of H. sabdariffa to decrease global oxidative stress is an important mechanism by which this natural product exerts its beneficial effects against arterial hypertension [46] [47] [48] . Hibiscus sabdariffa is rich in polyphenolic antioxidants, and polyphenols are known to improve endothelial function and decrease BP through regulating nitric oxide bioavailability [49] . Moreover, polyphenols and hibiscus acid from H. sabdariffa calyxes have been suggested as phytochemicals responsible for the antihypertensive effects of this plant [19] .
In experimental studies, aqueous extracts of H. sabdariffa calyxes and petals at doses ranging from 1 to 1000 mg/ kg/day were effective in decreasing BP [17, 50] . There has been no evidence of hepatic or renal toxicity due to H. sabdariffa extract consumption, except for possible adverse hepatic effects at high doses of 300 mg/kg per day of H. sabdariffa over a 3-month period [19, 51] . However, caution should be exercised in concomitant ingestion of H. sabdariffa along with antihypertensive drugs. An experimental study revealed a possible herb-drug interaction between hydrochlorothiazide (10 mg/kg) and H. sabdariffa extract (20-40 mg/kg). Administration of both the extract and the drug produced a significant increase in the volume of urine excreted and decreased the concentrations of sodium, bicarbonate, chloride ions, and pH of urine [52] .
Positive results of this meta-analysis support multifaceted and likely synergistic mechanisms that could be responsible for the hypotensive action of polyphenol-rich H. sabdariffa, and provide further evidence to the traditional use of the plant as a potential antihypertensive agent. The inverse association between baseline BP and magnitude of reduction in BP associated with daily sour tea consumption might have a particular implication for the management of high optimal BP (prehypertension) -a condition with increasing global prevalence that might predispose to hypertension incidence and related cardiovascular outcomes [53, 54] . The public health effects of daily consumption of H. sabdariffa could be crucial, since a small decrease in population-wide BP can be related to the prevention of progression of high optimal BP (prehypertension) to overt hypertension, of considerable decrease of cardiovascular risk in hypertensive patients [53, 54] . Furthermore, a reduction of 7.6/3.5 mmHg might have important cardiovascular implications since the results of Heart Outcome Evaluation study demonstrated that a 3.3/1.4 mmHg reduction was associated with a 22% decrease of relative risk of myocardial infarction, stroke, and cardiovascular mortality [55] . Drugs are obviously the primary treatment for hypertension, but the adherence to drug regimens is essentially decreased ($50%) [56] . Poor adherence to antihypertensive drugs and side effects of them could be significant factors contributing to uncontrolled BP [56] . Therefore, H. sabdariffa might be utilized as a possible new effective and safe supplementary option to better prevent and control hypertension.
Limitations of the study
The present meta-analysis had several limitations. Most importantly, eligible RCTs involved in this meta-analysis had small populations. It should be also noticed that the control groups differed in the studies included in this metaanalysis; some patients were given black tea [3, 28] , and others diet [4] , green tea [29] , and placebo [9] . Furthermore, different effects were observed in the different study populations. The BP-lowering effect was À9.15 mmHg for SBP and À4.42 mmHg for DBP in healthy individuals [4] . SBP was reduced by 5.5% and DBP by 4.0% in prehyrpentensive and mildly hypertensive adults [9] ; and by 15.4 and 4.3% in SBP and DBP, respectively, in prehypertension and stage I hypertensive patients [28] . Small numbers of participants was the reason that no additional analyses in the given subgroups were possible to perform. Furthermore, the studies included in this meta-analysis had short durations of follow-up.
Many attributes that differ within studies might be the causes of between-study heterogeneity, such as the year of publication, the type of study, the diagnosis criteria, and conditions of preparation of H. sabdariffa (infusion, decoctions, and extraction), the sample size, control group or quality. We used 'leave-one-out' sensitivity analysis under a conservative random-effects model to assess the possibility of some bias such as unclear double-randomization or large unbalanced dropout. Our results clearly indicate that the significance of estimated pooled effect size is not biased by any single study.
In conclusion, the findings of the present meta-analysis, being the first of its kind, confirm the potential effectiveness of supplementation with sour tea in reducing both SBP and DBP. These findings favor the traditional use of this natural, safe, and inexpensive supplement in patients with essential hypertension. However, further large-scale, well designed trials are needed, particularly those in which changes in SBP and DBP are the main outcomes, in order to finally confirm the place of H. sabdariffa as an alternative natural treatment for the hypertension management in routine clinical practice. Finally, potential interactions between H. sabdariffa supplements and antihypertensive medications, as well as the optimal dose of H. sabdariffa, must be still identified in order to optimize combination therapy. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension
